All In Biotech

Drug Trial Radar · NCT01965132

Korean College of Rheumatology Biologics and Targeted Therapy Registry

Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Dec 1, 2012

Primary completion

Dec 31, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 18, 2013

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.

Conditions

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis

Interventions

  • Biologic or targeted synthetic DMARDDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events during the use of biologics or targeted synthetic DMARDs in Korean patients with Rheumatic diseasesTime frame: up to 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul Metropolitan Government-Seoul National University Boramae Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.